Gastric carcinoids: between underestimation and overtreatment.
Gastric carcinoids (GCs), which originate from gastric enterochromaffin-like (ECL) mucosal cells and account for 2.4% of all carcinoids, are found increasingly in the course of upper gastrointestinal tract endoscopy. Current nosography includes those occurring in chronic conditions with hypergastrinemia, as the type 1 associated with chronic atrophic gastritis, and the type 2 associated with Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1, and type 3, which is unrelated to hypergastrinemia and is frequently malignant, with distant metastases. The optimal clinical approach to GCs remains to be elucidated, depending upon type, size and number of carcinoids. While there is agreement concerning the treatment of type 3 carcinoids, for types 1 and 2, current possibilities include simple surveillance, endoscopic polypectomy, surgical excision, associated or not with surgical antrectomy, or total gastrectomy. Moreover, the recent introduction of somatostatin analogues represents a therapeutic option of possibly outstanding relevance.
Gastroenterology Unit II, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via F. Sforza 35, 20122 Milano, Italy. sara.massironi@unimi.it
Sara
S
Massironi
Valentina
V
Sciola
Matilde-Pia
MP
Spampatti
Maddalena
M
Peracchi
Dario
D
Conte
D002276:Carcinoid Tumor / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*
D013004:Somatostatin